Feng Zhao

Feng Zhao


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
LWLei Wu
Lei Wu
YZYan Zhang
Yan Zhang
XGXiaoya Guo
Xiaoya Guo
XTXing Tang
Xing Tang
KXKeke Xin
Keke Xin
FZFeng Zhao
Feng Zhao
Background: Rosai-Dorfman disease (RDD) is a rare benign non-langerhans cell histiocytosis, mainly involving lymph nodes and skin. It is even rarer occurring only in central airway of lung and in diffuse form. Central airway RDD is similar to malignant tumor in imaging by radiological method and in bronchoscopy features. It is difficult to differentiate it from primary airway malignant tumor and to diagnose correctively in time. Case presentation: Here we present a rare case of 18-year-old male diagnosed with primary diffuse RDD in central airway. Although the features examined by enhanced chest computed tomography, positron emission tomography/computed tomography, diffusion-weighted imaging of enhanced chest MRI and bronchoscopy indicate to be malignant tumor, the patient was definitely confirmed by multiple transbronchial biopsies and immunohistochemistry. After two transbronchial resections, the patient's symptoms of paroxysmal cough, whistle sound and shortness of breath were significantly reduced, as well as the airway stenosis was significantly improved. After 5 months of follow-up, the patient had no symptoms and the central airway were unobstructed. Conclusions: Primary diffuse RDD in central airway is characterized by intratracheal neoplasm, which is usually suspected as malignant tumor according to radiological image and bronchoscopy. Pathology and immunohistochemistry are necessary for definite diagnosis. Transbronchial resection is effective and safe for patients with primary diffuse RDD in central airway.

24 June 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
LXLiangliang Xing
Liangliang Xing
LXLeidi Xu
Leidi Xu
YZYong Zhang
Yong Zhang
YCYinggang Che
Yinggang Che
MWMin Wang
Min Wang
JZJian Zhang
Jian Zhang
SCFFBXW7 E3 ubiquitin ligase complex is a crucial enzyme of the ubiquitin proteasome system that participates in variant activities of cell process, and its component FBXW7 (F-box and WD repeat domain–containing 7) is responsible for recognizing and binding to substrates. The expression of FBXW7 is controlled by multiple pathways at different levels. FBXW7 facilitates the maturity and function maintenance of immune cells via functioning as a mediator of ubiquitination-dependent degradation of substrate proteins. FBXW7 deficiency or mutation results in the growth disturbance and dysfunction of immune cell, leads to the resistance against immunotherapy, and participates in multiple illnesses. It is likely that FBXW7 coordinating with its regulators and substrates could offer potential targets to improve the sensitivity and effects of immunotherapy. Here, we review the mechanisms of the regulation on FBXW7 and its tumor suppression role in immune filed among various diseases (mostly cancers) to explore novel immune targets and treatments.

18 November 2025 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
YWYazhen Wang
Yazhen Wang
ZGZichan Guo
Zichan Guo
AXAnqi Xu
Anqi Xu
ZFZhaoyue Fu
Zhaoyue Fu
YHYongli Hou
Yongli Hou
LCLihua Chen
Lihua Chen
Natural killer (NK) cell immunotherapy exhibits limited efficacy in non-small cell lung cancer (NSCLC) due to the suppressive tumor-associated immune microenvironment. Previous studies have shown that interleukin-6 (IL-6) contributes to NK cell dysfunction and decreases NKp30 expression. However, the underlying mechanisms warrant further investigation. In this study, we identified elevated IL-6 and reduced NKp30 expression correlating with NK cell dysfunction and poor prognosis in NSCLC patients. Tumoral IL-6 inversely regulated NKp30 both clinically and in vitro. Mechanistically, IRE1α-XBP1s signaling activated IL-6 transcription via XBP1s binding to the -1201/-300 promoter region. IL-6 induced STAT3-dependent UBE2S upregulation, promoting ubiquitin-mediated NKp30 degradation in NK cells. This dual regulation establishes an XBP1s/IL-6/STAT3-UBE2S axis driving NKp30 loss and functional impairment. Our findings reveal tumor-intrinsic mechanisms suppressing NK cell activity in NSCLC, proposing XBP1s, IL-6, and UBE2S as actionable targets to enhance NK-based immunotherapies.


1 January 2006 in Journal of Asthma
Verified
Journal Article
Closed access
YLY. Liu
Y. Liu
PSP. Saccucci
P. Saccucci
HQHongbo Qi
Hongbo Qi
HWH. C. Wu
H. C. Wu
FZFeng Zhao
Feng Zhao
FGF. Gloria-Bottini
F. Gloria-Bottini
We have studied a sample of 120 asthmatic patients and 116 healthy control subjects from the Chinese Han population. Three polymorphic sites: ADA(1), ADA(2), and ADA(6), within the ADA gene have been examined. The proportion of carriers of *2 allele at locus ADA(1) is drastically reduced in asthmatics as compared to controls. There is an epistatic interaction of ADA(2) on the ADA(1) site characterized by a suppressive effect by the *2 allele of ADA(2) on the protective effect exerted by the *2 allele of ADA(1) site on susceptibility to asthma. Our data suggest the presence of some DNA sequences influencing the susceptibility to asthma are located in the area between ADA(1) and ADA(2) sites.

1 October 2023 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
MWMin Wang
Min Wang
YZYong Zhang
Yong Zhang
MLMingchuan Liu
Mingchuan Liu
YWYuanyong Wang
Yuanyong Wang
XNXiaona Niu
Xiaona Niu
JZJian Zhang
Jian Zhang
Background: Evidence for the effects of immunotherapy in non-small cell lung cancer (NSCLC) patients with distant organ metastasis is insufficient, and the predictive efficacy of established markers in tissue and blood is elusive. Our study aimed to determine the prognostic factors and develop a survival prognosis model for these patients. Methods: A total of 100 advanced NSCLC patients with distant organ metastases, who received single or combination immune checkpoint inhibitors (ICIs) in Xijing Hospital between June 2018 and June 2021, were enrolled for retrospective analysis. The major clinicopathological parameters were collected, and associated survival outcomes were followed up by telephone or inpatient follow-up for nearly 3 years to assess prognoses. The survival prognosis model was established based on univariate and multivariate Cox regression analyses to determine the candidate prognostic factors. Results: From the start of immunotherapy to the last follow-up, 77 patients progressed and 42 patients died, with a median follow-up of 18 months [95% confidence interval (CI): 15–19.9]. The median progression-free survival (PFS) and overall survival (OS) were 8 months (95% CI: 5.6–10.4) and 21 months (95% CI: 8.9–33.1), respectively. Multivariate Cox proportional hazards analysis showed Eastern Cooperative Oncology Group performance status (ECOG PS), body mass index (BMI), age-adjusted Charlson comorbidity index (ACCI), lactate dehydrogenase (LDH), and absolute neutrophil count (ANC) were correlated significantly with OS. Based on these five predictive factors, a nomogram and corresponding dynamic web page were constructed with a concordance index (C-index) of 0.81 and a 95% CI of 0.778–0.842. Additionally, the calibration plot and time-receiver operating characteristic (ROC) curve validated the precision of the model at 6-, 12-, and 18-month area under the curves (AUCs) reached 0.934, 0.829, and 0.846, respectively. According to the critical point of the model, patients were further divided into a high-risk total point score (TPS) >258, middle-risk (204< TPS ≤258), and low-risk group (TPS ≤204), and significant OS differences were observed among the three subgroups (median OS: 4.8 vs. 13.0 vs. 32.9 months). Conclusions: A feasible and practical model based on clinical characteristics has been developed to predict the prognosis of NSCLC patients with distant organ metastasis undergoing immunotherapy.